Is Tirzepatide a Subcutaneous Injection — and What Does That Mean?

Step 1: understanding why the subcutaneous route is used

Tirzepatide is a peptide molecule (a chain of amino acids) and peptides are broken down by stomach acid before they reach the bloodstream if swallowed. That is why the medicine is given subcutaneously rather than as an oral tablet. When injected into the layer of fat just under the skin, it is absorbed gradually into the capillaries and from there into general circulation, where it can act on the GIP and GLP-1 receptors that regulate appetite and blood-sugar control.

The NHS patient information for tirzepatide confirms the three approved injection sites: the abdomen (avoiding the area around the navel), the front of the thigh, and the outer upper arm. All three sit in subcutaneous tissue rather than muscle, which matters, an intramuscular injection of the same medicine would alter its absorption profile and is not the correct technique.

One thing people often find reassuring once they start: the needle itself is short and fine. The injection does not feel the way most people expect from memories of childhood vaccinations. That said, it is completely normal to feel a little apprehensive before the first dose. Most patients say by the second or third week it has become as unremarkable as any other weekly habit. You can read more about what this treatment involves on the Mounjaro overview page, which covers the full picture of how the medicine is prescribed and used in the UK.

Step 2: using the KwikPen, the practical sequence

Tirzepatide is sold in the UK under the brand name Mounjaro and comes in a pre-filled, multi-dose KwikPen. One pen contains four doses, one per week for a month. You do not draw up liquid or assemble parts before injecting; the pen handles the dose mechanically.

The standard sequence each week runs like this: let the pen reach room temperature for around thirty minutes if it has been stored in the fridge; clean the chosen skin site; pinch the skin gently if you are lean at that site; press the pen against the skin at a 90-degree angle; hold the button until the injection is complete and the window changes. Rotate where on the body you inject each time, using the same small patch of skin repeatedly can cause lumps under the skin called lipohypertrophy, which slows absorption.

Storage matters too. The pen should be kept refrigerated between 2°C and 8°C, but there is a limited period during which it can be kept at room temperature, the exact window is specified in the Patient Information Leaflet that comes with your pen, and that is the document to follow rather than any general guidance online. For a broader overview of how tirzepatide compares with other options, the Mounjaro or tirzepatide page explains the naming and what to expect from treatment.

Step 3: dose titration and what changes under the skin over time

Treatment begins at 2.5 mg per week. The starting dose exists to allow the body to adjust gradually, gastrointestinal side effects such as nausea are most common in the early weeks and are less pronounced when the dose climbs slowly. A prescriber, not the patient, determines the pace of any increase, typically moving up in 4-week steps through 5 mg, 7.5 mg, 10 mg, 12.5 mg and up to 15 mg if tolerated and clinically appropriate.

The subcutaneous route supports this controlled release. Because absorption from fatty tissue is relatively slow compared with intravenous administration, each weekly injection produces a gradual rise and fall in blood concentration rather than a sharp spike, which is part of why a once-weekly injection is sufficient. Clinical trial data published in the New England Journal of Medicine (SURMOUNT-1) showed that adults on tirzepatide 15 mg achieved an average weight reduction of around 20–21% over 72 weeks, a result that reflects the medicine working consistently at its site of action week after week.

Whether tirzepatide is right for you depends on factors beyond BMI alone, your prescriber weighs your health history, current medicines and any conditions that might affect suitability. Our guide on tirzepatide and Mounjaro covers how the two names relate and what the licensed UK product actually looks like. If you are curious about how tirzepatide is licensed in the UK specifically, that page covers the regulatory detail. For a sense of what private treatment costs, the Mounjaro cost page sets out what a transparent, all-included price covers.

What the injection route means for side effects

The most common side effects of tirzepatide are gastrointestinal: nausea, constipation, diarrhoea, indigestion and occasional burping. These arise from the medicine's action on the gut, not from the injection itself. Locally, the injection site may occasionally be slightly red, itchy or tender, rotating sites helps keep this minimal.

On safety, the MHRA issued a Drug Safety Update in January 2026 highlighting acute pancreatitis as a known but infrequent risk with GLP-1 class medicines. The key symptom to take seriously is severe stomach pain that spreads to the back, especially if accompanied by vomiting, that warrants urgent medical attention. The MHRA Yellow Card scheme allows patients and carers to report any suspected side effects, and doing so helps regulators monitor the medicine's safety profile across the UK population.

If you have questions about technique, missed doses or how to manage a side effect, that conversation belongs with your prescriber or the Patient Information Leaflet, not a forum. Our FAQs page covers some of the questions most often raised at consultation stage, and our support team is available seven days a week once you are a patient. When you are ready to explore whether treatment is suitable for you, our free consultation is the place to start, check your eligibility and a GPhC-registered prescriber will review your answers the same day.